http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최성구,홍성도,김승태 대한소아청소년정신의학회 1997 소아청소년정신의학 Vol.8 No.1
본 연구는 아동의 기질특성이 신체발육에 영향을 주는가를 알아보기 위해 설계되었다. Thomas와 Chess에 의해 개발된 기질설문지의 한국 표준화 판을 이용하여 3세에서 7세 사이의 남녀 아동 395명의 기질을 측정하였다. 동시에 각 아동의 신장과 체중을 측정한 후 한국 소아 신체 발육 표준치에 근거하여 신장 및 체중 절대치를 백분율 값으로 전환하였다. 기질의 난이도 지수인 요인 A점수 및 9가지 기질범주 점수와 신장 및 체중 백분율 값 및 신장에 따른 체중 백분율 값 사이에 상관분석을 실시하였다. 가족 평균 월 수입액에 따라 7단계로 분류한 가정 경제력을 통제변수로 하여 경제력을 통제하였다. 그 결과 기질적으로 어려운 아이일수록 동일 연령의 아동들에 비해 체중이 낮았으며, 동일한 신장을 갖는 아동들 중에서도 체중이 낮은 쪽에 포함되었다. 이런 경향은 여자 아동들에게서 두드러졌다. 이 결과는 기질특성이 심리적 발달뿐만 아니라 신체 성장과도 관련이 있음을 보여주는 것이다. This study was designed to explore whether the temperament of a child influences the physical growth. The Korean version of the Parent Questionnaire for Children developed by Thomas, Chess and Korn was applied to 395 Korean children whose ages ranged from 3 years to 7 years. Simultaneously the height and the weight were measured for each child and converted into percentile scale according to the Growth Curve and the Weight Percentile Table for the Height of Korean children. Statistical analysis was performed among 9 temperamental categories, height and weight percentiles for the age and weight percentiles for the height using the first-order partial correlation analysis, controlling for the familial mean income per month. Results showed that the more temperamentally difficult a child is , the lower weight he has when compared with the children of the same age or the same height. Although there were some differences, the tendency of the above findings was maintained both in male and female children. These results show that the temperament may influence the physical growth as well as the psychological development.
Christov, Plamen P.,Yamanaka, Kinrin,Choi, Jeong-Yun,Takata, Kei-ichi,Wood, Richard D.,Guengerich, F. Peter,Lloyd, R. Stephen,Rizzo, Carmelo J. American Chemical Society 2012 Chemical research in toxicology Vol.25 No.8
<P><I>N</I><SUP>6</SUP>-(2-Deoxy-<SMALL>d</SMALL>-<I>erythro</I>-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-<I>N</I>-methylformamidopyrimidine (MeFapy-dGuo) has been identified as a stable DNA adduct that arises from the reaction of DNA with a variety of methylating agents. Since this lesion persists in DNA and may contribute to the overall mutagenesis from electrophilic methylating agents, the MeFapy-dGuo lesion was incorporated into oligonucleotides, and its replication bypass was examined in vitro with a panel of eukaryotic high fidelity (hPols α, β, and δ/PCNA) and translesion (hPols η, κ, ι, Rev1, ν, and yPol ζ) polymerases to address its miscoding potential. The MeFapy-dGuo was found to be a strong block to the high fidelity polymerases at either the insertion or the extension step. Efficient translesion synthesis was observed for hPols η and κ, and the combined activities of hRev1 and yPol ζ. The nucleotide sequences of the extension products were determined by mass spectrometry. The error-free extension product was the most abundant product observed for each polymerase. Misreplication products, which included misinsertion of Thy, Gua, and Ade opposite the MeFapy-dGuo lesion, as well as an interesting one-nucleotide deletion product, were observed when hPols η and κ were employed; these events accounted for 8–29% of the total extension products observed. The distribution and abundance of the misreplication products were dependent on the polymerases and local sequence context of the lesion. Collectively, these data suggest that although MeFapy-dGuo adducts represent a relatively minor proportion of the total alkylated lesions, their miscoding potentials could significantly contribute to genomic instability.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/crtoec/2012/crtoec.2012.25.issue-8/tx300113e/production/images/medium/tx-2012-00113e_0001.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/tx300113e'>ACS Electronic Supporting Info</A></P>
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing
Yang, L.,Lee, M.S.,Lu, H.,Oh, D.Y.,Kim, Y.,Park, D.,Park, G.,Ren, X.,Bristow, Christopher A.,Haseley, Psalm S.,Lee, S.,Pantazi, A.,Kucherlapati, R.,Park, W.Y.,Scott, Kenneth L.,Choi, Y.L.,Park, Peter University of Chicago Press [etc.] 2016 American journal of human genetics Vol.98 No.5
<P>Although exome sequencing data are generated primarily to detect single-nucleotide variants and indels, they can also be used to identify a subset of genomic rearrangements whose breakpoints are located in or near exons. Using >4,600 tumor and normal pairs across 15 cancer types, we identified over 9,000 high confidence somatic rearrangements, including a large number of gene fusions. We find that the 50 fusion partners of functional fusions are often housekeeping genes, whereas the 30 fusion partners are enriched in tyrosine kinases. We establish the oncogenic potential of ROR1-DNAJC6 and CEP85L-ROS1 fusions by showing that they can promote cell proliferation in vitro and tumor formation in vivo. Furthermore, we found that similar to 4% of the samples have massively rearranged chromosomes, many of which are associated with upregulation of oncogenes such as ERBB2 and TERT. Although the sensitivity of detecting structural alterations from exomes is considerably lower than that from whole genomes, this approach will be fruitful for the multitude of exomes that have been and will be generated, both in cancer and in other diseases.</P>
Jun Mo Kim,Sukhyung Kang,Steve Sungwon Cho,Peter D. Chang,Jinseo Yang,Jin Pyeong Jeon,Hyuk Jai Choi 대한신경손상학회 2022 Korean Journal of Neurotrauma Vol.18 No.2
Objective: We present how to perform radiofrequency sensory stimulation (RFSS) and whether RFSS could be helpful in identifying symptomatic injured roots in multilevel lumbar stenosis. Methods: Consecutive patients who underwent RFSS from 2010 to 2012 were enrolled. To identify pathologic lesions, RFSS was performed for suspicious roots, as determined using lumbar magnetic resonance imaging (MRI). The RFSS procedure resembled transforaminal root block. During RFSS of the suspicious root, patients could indicate whether stimulation induced their usual pain and/or sensory changes and could indicate whether the same leg area was affected. The number of possible symptomatic roots on MRI was evaluated before and after RFSS. Based on the RFSS results, we confirmed the presence of symptomatic nerve root(s) and performed surgical decompression. Surgical results, such as numeric rating scale (NRS) scores for low back pain (LBP) and leg pain (LP), and Oswestry disability index (ODI), were evaluated. Results: Ten patients were enrolled in the study. Their mean age was 70.1±9.7 years. Clinically, NRS-LBP, NRS-LP, and ODI before surgery were 5.1%, 7.5%, and 53.2%, respectively. The mean number of suspicious roots was 2.6±0.8. After RFSS, the mean number of symptomatic roots was 1.6±1.0. On average, 1.4 lumbar segments were decompressed. The follow-up period was 35.3±12.8 months. At the last follow-up, NRS-LBP, NRS-LP, and ODI were 3.1%, 1.5%, and 35.3%, respectively. There was no recurrence or need for further surgical treatment for lumbar stenosis. Conclusion: RFSS is a potentially helpful diagnostic tool for verifying and localizing symptomatic injured root lesions, particularly in patients with multilevel spinal stenosis.
Kim, Seung Tae,Kim, Kyoung‐,Mee,Kim, Nayoung K.D.,Park, Joon Oh,Ahn, Soomin,Yun, Jae‐,Won,Kim, Kyu‐,Tae,Park, Se Hoon,Park, Peter J.,Kim, Hee Cheol,Sohn, Tae Sung,Choi, Dong Il,Cho, AlphaMed Press 2017 The oncologist Vol.22 No.10
<P>Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable 'precision medicine,' wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancer-related genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.</P>